Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Laboratory mice born to wild mice have natural microbiota and model human immune responses.

Rosshart SP, Herz J, Vassallo BG, Hunter A, Wall MK, Badger JH, McCulloch JA, Anastasakis DG, Sarshad AA, Leonardi I, Collins N, Blatter JA, Han SJ, Tamoutounour S, Potapova S, Foster St Claire MB, Yuan W, Sen SK, Dreier MS, Hild B, Hafner M, Wang D, Iliev ID, Belkaid Y, Trinchieri G, Rehermann B.

Science. 2019 Aug 2;365(6452). pii: eaaw4361. doi: 10.1126/science.aaw4361. Epub 2019 Aug 1.

PMID:
31371577
2.

Inflammation drives an altered phenotype of mucosal-associated invariant T cells in chronic hepatitis D virus infection.

Kefalakes H, Rehermann B.

J Hepatol. 2019 Aug;71(2):237-239. doi: 10.1016/j.jhep.2019.05.024. Epub 2019 Jun 17. No abstract available.

PMID:
31221499
3.

Hepatitis D Virus-Specific CD8+ T Cells Have a Memory-Like Phenotype Associated With Viral Immune Escape in Patients With Chronic Hepatitis D Virus Infection.

Kefalakes H, Koh C, Sidney J, Amanakis G, Sette A, Heller T, Rehermann B.

Gastroenterology. 2019 May;156(6):1805-1819.e9. doi: 10.1053/j.gastro.2019.01.035. Epub 2019 Jan 18.

PMID:
30664876
4.

Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.

Rehermann B, Thimme R.

Gastroenterology. 2019 Jan;156(2):369-383. doi: 10.1053/j.gastro.2018.08.061. Epub 2018 Sep 26. Review.

PMID:
30267712
5.

Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy.

Alao H, Cam M, Keembiyehetty C, Zhang F, Serti E, Suarez D, Park H, Fourie NH, Wright EC, Henderson WA, Li Q, Liang TJ, Rehermann B, Ghany MG.

Hepatology. 2018 Dec;68(6):2078-2088. doi: 10.1002/hep.29921. Epub 2018 Jul 16.

PMID:
29704252
6.

Mucosal-Associated Invariant T Cells in Chronic Inflammatory Liver Disease.

Bolte FJ, Rehermann B.

Semin Liver Dis. 2018 Feb;38(1):60-65. doi: 10.1055/s-0037-1621709. Epub 2018 Feb 22. Review.

7.

Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors.

Giannelou A, Wang H, Zhou Q, Park YH, Abu-Asab MS, Ylaya K, Stone DL, Sediva A, Sleiman R, Sramkova L, Bhatla D, Serti E, Tsai WL, Yang D, Bishop K, Carrington B, Pei W, Deuitch N, Brooks S, Edwan JH, Joshi S, Prader S, Kaiser D, Owen WC, Sonbul AA, Zhang Y, Niemela JE, Burgess SM, Boehm M, Rehermann B, Chae J, Quezado MM, Ombrello AK, Buckley RH, Grom AA, Remmers EF, Pachlopnik JM, Su HC, Gutierrez-Cruz G, Hewitt SM, Sood R, Risma K, Calvo KR, Rosenzweig SD, Gadina M, Hafner M, Sun HW, Kastner DL, Aksentijevich I.

Ann Rheum Dis. 2018 Apr;77(4):612-619. doi: 10.1136/annrheumdis-2017-212401. Epub 2018 Jan 22.

8.

Non-classical Immunity Controls Microbiota Impact on Skin Immunity and Tissue Repair.

Linehan JL, Harrison OJ, Han SJ, Byrd AL, Vujkovic-Cvijin I, Villarino AV, Sen SK, Shaik J, Smelkinson M, Tamoutounour S, Collins N, Bouladoux N, Dzutsev A, Rosshart SP, Arbuckle JH, Wang CR, Kristie TM, Rehermann B, Trinchieri G, Brenchley JM, O'Shea JJ, Belkaid Y.

Cell. 2018 Feb 8;172(4):784-796.e18. doi: 10.1016/j.cell.2017.12.033. Epub 2018 Jan 18.

9.

The role of genetics in hepatic fibrosis among hepatitis C virus patients.

Park H, O'Brien TR, Rehermann B.

Hepatology. 2018 May;67(5):2043-2045. doi: 10.1002/hep.29659. Epub 2018 Mar 25. No abstract available.

PMID:
29152758
10.

Wild Mouse Gut Microbiota Promotes Host Fitness and Improves Disease Resistance.

Rosshart SP, Vassallo BG, Angeletti D, Hutchinson DS, Morgan AP, Takeda K, Hickman HD, McCulloch JA, Badger JH, Ajami NJ, Trinchieri G, Pardo-Manuel de Villena F, Yewdell JW, Rehermann B.

Cell. 2017 Nov 16;171(5):1015-1028.e13. doi: 10.1016/j.cell.2017.09.016. Epub 2017 Oct 19.

11.

Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation.

Bolte FJ, O'Keefe AC, Webb LM, Serti E, Rivera E, Liang TJ, Ghany M, Rehermann B.

Gastroenterology. 2017 Nov;153(5):1392-1403.e2. doi: 10.1053/j.gastro.2017.07.043. Epub 2017 Aug 2.

12.

Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages.

Cheng X, Xia Y, Serti E, Block PD, Chung M, Chayama K, Rehermann B, Liang TJ.

Hepatology. 2017 Dec;66(6):1779-1793. doi: 10.1002/hep.29348.

13.

Tissue-resident T cells in hepatitis B: A new target for cure?

Bolte FJ, Rehermann B.

J Exp Med. 2017 Jun 5;214(6):1564-1566. doi: 10.1084/jem.20170842. Epub 2017 May 19.

14.

Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics.

Block TM, Locarnini S, McMahon BJ, Rehermann B, Peters MG.

Clin Infect Dis. 2017 May 1;64(9):1283-1288. doi: 10.1093/cid/cix129. Review.

15.

Systemic toxoplasma infection triggers a long-term defect in the generation and function of naive T lymphocytes.

Kugler DG, Flomerfelt FA, Costa DL, Laky K, Kamenyeva O, Mittelstadt PR, Gress RE, Rosshart SP, Rehermann B, Ashwell JD, Sher A, Jankovic D.

J Exp Med. 2016 Dec 12;213(13):3041-3056. Epub 2016 Nov 14.

16.

Mature peritoneal macrophages take an avascular route into the injured liver and promote tissue repair.

Rehermann B.

Hepatology. 2017 Jan;65(1):376-379. doi: 10.1002/hep.28883. Epub 2016 Nov 15. No abstract available.

17.

Peptide-dependent HLA-KIR-mediated regulation of NK cell function.

Rehermann B.

J Hepatol. 2016 Aug;65(2):237-9. doi: 10.1016/j.jhep.2016.05.008. Epub 2016 May 17. No abstract available.

PMID:
27212248
18.

R2d2 Drives Selfish Sweeps in the House Mouse.

Didion JP, Morgan AP, Yadgary L, Bell TA, McMullan RC, Ortiz de Solorzano L, Britton-Davidian J, Bult CJ, Campbell KJ, Castiglia R, Ching YH, Chunco AJ, Crowley JJ, Chesler EJ, Förster DW, French JE, Gabriel SI, Gatti DM, Garland T Jr, Giagia-Athanasopoulou EB, Giménez MD, Grize SA, Gündüz İ, Holmes A, Hauffe HC, Herman JS, Holt JM, Hua K, Jolley WJ, Lindholm AK, López-Fuster MJ, Mitsainas G, da Luz Mathias M, McMillan L, Ramalhinho Mda G, Rehermann B, Rosshart SP, Searle JB, Shiao MS, Solano E, Svenson KL, Thomas-Laemont P, Threadgill DW, Ventura J, Weinstock GM, Pomp D, Churchill GA, Pardo-Manuel de Villena F.

Mol Biol Evol. 2016 Jun;33(6):1381-95. doi: 10.1093/molbev/msw036. Epub 2016 Feb 15.

19.

HCV in 2015: Advances in hepatitis C research and treatment.

Rehermann B.

Nat Rev Gastroenterol Hepatol. 2016 Feb;13(2):70-2. doi: 10.1038/nrgastro.2015.227. Epub 2016 Jan 21. Review.

PMID:
26790365
20.

Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.

Serti E, Park H, Keane M, O'Keefe AC, Rivera E, Liang TJ, Ghany M, Rehermann B.

Gut. 2017 Apr;66(4):724-735. doi: 10.1136/gutjnl-2015-310033. Epub 2016 Jan 4.

PMID:
26733671
21.

Natural Killer Cells in Viral Hepatitis.

Rehermann B.

Cell Mol Gastroenterol Hepatol. 2015 Nov;1(6):578-588.

22.

Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study.

Noureddin M, Rotman Y, Zhang F, Park H, Rehermann B, Thomas E, Liang TJ.

Genes Immun. 2015 Jul-Aug;16(5):321-9. doi: 10.1038/gene.2015.11. Epub 2015 May 28.

23.

Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.

Serti E, Chepa-Lotrea X, Kim YJ, Keane M, Fryzek N, Liang TJ, Ghany M, Rehermann B.

Gastroenterology. 2015 Jul;149(1):190-200.e2. doi: 10.1053/j.gastro.2015.03.004. Epub 2015 Mar 6.

24.

T cell responses in hepatitis C virus infection: historical overview and goals for future research.

Holz L, Rehermann B.

Antiviral Res. 2015 Feb;114:96-105. doi: 10.1016/j.antiviral.2014.11.009. Epub 2014 Nov 26. Review.

25.

Durability of antibody response against hepatitis B virus in healthcare workers vaccinated as adults.

Gara N, Abdalla A, Rivera E, Zhao X, Werner JM, Liang TJ, Hoofnagle JH, Rehermann B, Ghany MG.

Clin Infect Dis. 2015 Feb 15;60(4):505-13. doi: 10.1093/cid/ciu867. Epub 2014 Nov 10.

26.

Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.

Rehermann B, Bertoletti A.

Hepatology. 2015 Feb;61(2):712-21. doi: 10.1002/hep.27323. Review.

27.

Trace amounts of sporadically reappearing HCV RNA can cause infection.

Veerapu NS, Park SH, Tully DC, Allen TM, Rehermann B.

J Clin Invest. 2014 Aug;124(8):3469-78. doi: 10.1172/JCI73104. Epub 2014 Jul 8.

28.

Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection.

Werner JM, Serti E, Chepa-Lotrea X, Stoltzfus J, Ahlenstiel G, Noureddin M, Feld JJ, Liang TJ, Rotman Y, Rehermann B.

Hepatology. 2014 Oct;60(4):1160-9. doi: 10.1002/hep.27092. Epub 2014 Aug 13.

29.

Monocytes activate natural killer cells via inflammasome-induced interleukin 18 in response to hepatitis C virus replication.

Serti E, Werner JM, Chattergoon M, Cox AL, Lohmann V, Rehermann B.

Gastroenterology. 2014 Jul;147(1):209-220.e3. doi: 10.1053/j.gastro.2014.03.046. Epub 2014 Mar 28.

30.

Hepatitis C virus attenuates interferon-induced major histocompatibility complex class I expression and decreases CD8+ T cell effector functions.

Kang W, Sung PS, Park SH, Yoon S, Chang DY, Kim S, Han KH, Kim JK, Rehermann B, Chwae YJ, Shin EC.

Gastroenterology. 2014 May;146(5):1351-60.e1-4. doi: 10.1053/j.gastro.2014.01.054. Epub 2014 Jan 31.

31.

Immune responses to HCV and other hepatitis viruses.

Park SH, Rehermann B.

Immunity. 2014 Jan 16;40(1):13-24. doi: 10.1016/j.immuni.2013.12.010. Review.

32.

Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection.

Park SH, Veerapu NS, Shin EC, Biancotto A, McCoy JP, Capone S, Folgori A, Rehermann B.

Nat Med. 2013 Dec;19(12):1638-42. doi: 10.1038/nm.3408. Epub 2013 Nov 24.

33.

Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection?

Hara K, Rivera MM, Koh C, Demino M, Page S, Nagabhyru PR, Rehermann B, Liang TJ, Hoofnagle JH, Heller T.

J Infect Dis. 2014 Jan 1;209(1):38-45. doi: 10.1093/infdis/jit541. Epub 2013 Oct 14.

34.

The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity.

Werner JM, Abdalla A, Gara N, Ghany MG, Rehermann B.

Gastroenterology. 2013 Nov;145(5):1026-34. doi: 10.1053/j.gastro.2013.07.044. Epub 2013 Jul 31.

35.

Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells.

Rehermann B.

Nat Med. 2013 Jul;19(7):859-68. doi: 10.1038/nm.3251. Review.

36.

Occupational exposure to hepatitis C virus: early T-cell responses in the absence of seroconversion in a longitudinal cohort study.

Heller T, Werner JM, Rahman F, Mizukoshi E, Sobao Y, Gordon AM, Sheets A, Sherker AH, Kessler E, Bean KS, Herrine SK, Stevens M, Schmitt J, Rehermann B.

J Infect Dis. 2013 Sep;208(6):1020-5. doi: 10.1093/infdis/jit270. Epub 2013 Jun 24.

37.

Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection.

Werner JM, Heller T, Gordon AM, Sheets A, Sherker AH, Kessler E, Bean KS, Stevens M, Schmitt J, Rehermann B.

Hepatology. 2013 Nov;58(5):1621-31. doi: 10.1002/hep.26353. Epub 2013 Sep 30.

38.

Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.

Rotman Y, Noureddin M, Feld JJ, Guedj J, Witthaus M, Han H, Park YJ, Park SH, Heller T, Ghany MG, Doo E, Koh C, Abdalla A, Gara N, Sarkar S, Thomas E, Ahlenstiel G, Edlich B, Titerence R, Hogdal L, Rehermann B, Dahari H, Perelson AS, Hoofnagle JH, Liang TJ.

Gut. 2014 Jan;63(1):161-9. doi: 10.1136/gutjnl-2012-303852. Epub 2013 Feb 8.

39.

The frequency of CD127(+) hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection.

Shin EC, Park SH, Nascimbeni M, Major M, Caggiari L, de Re V, Feinstone SM, Rice CM, Rehermann B.

J Virol. 2013 Apr;87(8):4772-7. doi: 10.1128/JVI.03122-12. Epub 2013 Feb 6.

40.

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.

Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR.

Nat Genet. 2013 Feb;45(2):164-71. doi: 10.1038/ng.2521. Epub 2013 Jan 6.

41.

Reply: b-cell frequency in HCV-related mixed cryoglobulinemia.

Holz LE, Yoon JC, Raghuraman S, Moir S, Sneller MC, Rehermann B.

Hepatology. 2013 Jul;58(1):448-9. doi: 10.1002/hep.26112. Epub 2013 May 29. No abstract available.

PMID:
23111813
42.

IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection.

Park H, Serti E, Eke O, Muchmore B, Prokunina-Olsson L, Capone S, Folgori A, Rehermann B.

Hepatology. 2012 Dec;56(6):2060-70. doi: 10.1002/hep.25897. Epub 2012 Nov 19.

43.

Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus.

Park SH, Shin EC, Capone S, Caggiari L, De Re V, Nicosia A, Folgori A, Rehermann B.

Gastroenterology. 2012 Oct;143(4):1048-60.e4. doi: 10.1053/j.gastro.2012.06.005. Epub 2012 Jun 13.

44.

B cell homeostasis in chronic hepatitis C virus-related mixed cryoglobulinemia is maintained through naïve B cell apoptosis.

Holz LE, Yoon JC, Raghuraman S, Moir S, Sneller MC, Rehermann B.

Hepatology. 2012 Nov;56(5):1602-10. doi: 10.1002/hep.25821. Epub 2012 Oct 14.

45.

Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes.

Busch MP, Murthy KK, Kleinman SH, Hirschkorn DF, Herring BL, Delwart EL, Racanelli V, Yoon JC, Rehermann B, Alter HJ.

Blood. 2012 Jun 28;119(26):6326-34. doi: 10.1182/blood-2011-12-393637. Epub 2012 Apr 12.

46.

The clinical relevance of persistent recombinant immunoblot assay-indeterminate reactions: insights into the natural history of hepatitis C virus infection and implications for donor counseling.

Makuria AT, Raghuraman S, Burbelo PD, Cantilena CC, Allison RD, Gibble J, Rehermann B, Alter HJ.

Transfusion. 2012 Sep;52(9):1940-8. doi: 10.1111/j.1537-2995.2011.03524.x. Epub 2012 Feb 5.

47.

Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion.

Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B.

J Infect Dis. 2012 Mar 1;205(5):763-71. doi: 10.1093/infdis/jir835. Epub 2012 Jan 31.

48.

Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.

Edlich B, Ahlenstiel G, Zabaleta Azpiroz A, Stoltzfus J, Noureddin M, Serti E, Feld JJ, Liang TJ, Rotman Y, Rehermann B.

Hepatology. 2012 Jan;55(1):39-48. doi: 10.1002/hep.24628. Epub 2011 Nov 14.

49.

Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.

Ahlenstiel G, Edlich B, Hogdal LJ, Rotman Y, Noureddin M, Feld JJ, Holz LE, Titerence RH, Liang TJ, Rehermann B.

Gastroenterology. 2011 Oct;141(4):1231-9, 1239.e1-2. doi: 10.1053/j.gastro.2011.06.069. Epub 2011 Jul 7.

50.

Delayed induction, not impaired recruitment, of specific CD8⁺ T cells causes the late onset of acute hepatitis C.

Shin EC, Park SH, Demino M, Nascimbeni M, Mihalik K, Major M, Veerapu NS, Heller T, Feinstone SM, Rice CM, Rehermann B.

Gastroenterology. 2011 Aug;141(2):686-95, 695.e1. doi: 10.1053/j.gastro.2011.05.006. Epub 2011 May 18.

Supplemental Content

Loading ...
Support Center